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ABSTRACT: Neurotuberculosis is a serious disease, occurring 
in about 5 to 10% of cases of extrapulmonary tuberculosis. The 
clinical spectrum varies according to the affected site (meningeal, 
cerebral parenchyma or spinal cord). Herein we present the 
case of a 32-year-old male patient with cough and weight loss 
who presented with hemiparesis and disorientation, receiving a 
diagnosis of neurotuberculosis using the Xpert MTB / RIF® test. 
The present case aims to report the clinical and neuroimaging 
data of an immunocompetent patient with neurotuberculosis.
The definitive diagnosis is made by the detection of tuberculosis 
bacilli in cerebrospinal fluid. The RIF® Xpert MTB test has 
similar sensitivity and specificity to other diagnostic methods 
for tuberculosis and the advantage of providing information on 
resistance to rifampicin. The prognosis depends on the stage and 
onset of treatment. 
Keywords: Tuberculosis; Tuberculosis, meningeal; Tuberculosis, 
central nervous system; Immune system; Mycobacterium 
tuberculosis.
RESUMO: A neurotuberculose é uma doença grave, ocorrendo 
em cerca de 5 a 10% dos casos de tuberculose extrapulmonar. O 
espectro clínico varia de acordo com o local afetado (meninge, 
parênquima cerebral ou medula espinhal). Aqui, apresentamos o 
caso de um paciente do sexo masculino de 32 anos com quadro 
de tosse e perda de peso que apresentou à admissão hemiparesia 
e desorientação, recebendo diagnóstico de neurotuberculose 
através do teste Xpert MTB/RIF®. O presente caso objetiva 
relatar os dados clínicos e de neuroimagem de um paciente 
imunocompetente com neurotuberculose. O diagnóstico 
definitivo é feito pela detecção de bacilos da tuberculose no 
líquido cefalorraquidiano. O teste RIF® Xpert MTB apresenta 
sensibilidade e especificidade semelhantes a outros métodos de 
diagnóstico da tuberculose e a vantagem de fornecer informações 
sobre a resistência à rifampicina. O prognóstico depende do 
estágio e do início do tratamento. 
Descritores: Tuberculose; Tuberculose meníngea; Tuberculose 
do sistema nervoso central; Sistema imunitário; Mycobacterium 
tuberculosis.
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INTRODUCTION
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis that 
mainly affects lungs, but can also affects other organs 
such as pleura, ganglia, meninges, bone, kidney and 
others.1The occurrence is increased in people with human 
immunodeficiency virus (HIV), especially the severely 
immunocompromised. It is estimated that one-third of 
the world population is infected with Koch bacillus2. 
The occurrence of extrapulmonary tuberculosis (EPTB) 
in immunocompetent individuals is rare. In 2015, 10.4 
million new cases of TB were reported worldwide and 
which approximately 1.6 million died3. In 2005 in The 
United States, central nervous system (CNS) involvement 
was observed in 5 to 10% of EPTB cases4.
The clinical spectrum of extrapulmonary forms 
varies according to the affected site. Pleural tuberculosis 
is the most common form of EPTB in individuals without 
HIV. Neurotuberculosis is responsible for 3% of TB cases 
in seronegative HIV patients and up to 10% of cases in 
seropositive HIV patients. In these cases, there is slower 
subacute evolution than other meningitis. Despite adequate 
treatment, neurotuberculosis has a high mortality rate 
(ranges from 17-30%) and a high frequency of disabling 
morbidity5.
This study aims to report a clinical case of a 32-year-
old patient diagnosed with neurotuberculosis and discuss 
the clinical aspects, diagnosis, management and prognosis.
METHODS
The patient authorized publication of his case and 
image by written informed consent. The patient history 
and data were obtained from his medical report during the 
hospital stay in Hospital São José de Doenças Infecciosas 
(HSJ) in March 2017.
CASE REPORT
A 32-year-old man, unemployed (ex-convict), 
presented with a 3-month history of fever, dry cough, 
bloody vomiting, and unquantified weight loss. He reported 
1-month low back pain radiated to costal arches and, for 2 
weeks, presented disorientation and headache. He sought 
medical attention due to a focal convulsive crisis. He has 
reported using alcohol and marijuana since 17 years of age 
until 1 year ago. On admission, patient was disoriented, 
sleepy and febrile. He presented left facio-brachial-crural 
hemiparesis, right ptosis and altered ocular motricity in 
the third and fourth right cranial nerves. He denied any 
contact or familiar with tuberculosis. Fundoscopy revealed 
slight right blurring papilla. Heart and lung exams were 
normal. His abdomen was painful in right hypochondrium. 
Liver was palpable at right costal border. Elisa Anti-
HIV tested negative. Cranial Computed Tomography 
(CT) showed cerebral edema, mild hydrocephalus and 
meningeal enhancement (Figure 1). Cerebrospinal fluid 
(CSF) analysis showed an increase in white cells with a 
predominance of lymphocytes [white blood cell count of 
45 cells/mm3 (lymphocytes 79%)], no red blood cells, 
CSF glucose of 36mg/dL, and CSF protein of 157mg/dL. 
CSF gram and fungal stains, as well as bacterial cultures, 
tested negative. Xpert MTB/RIF® test was positive 
and sensitive to rifampicin. Then, the case was notified. 
Brain magnetic resonance imaging (MRI) showed diffuse 
hyperintense signal intensity delineating the cortical 
gyrus in FLAIR sequence, associated with intense diffuse 
leptomeningeal enhancement. There was a focus of altered 
signal in the right internal capsule appearing hypointense 
on T1-weighted and hyperintense on T2-weighted images, 
without significant enhancement by the venous contrast 
(Figure 2). Also, it could be demonstrated that there was an 
intense restriction at diffusion-weighted imaging. Dilated 
supratentorial ventricular system with transependymal 
edema was seen as well. The treatment of tuberculous 
meningitis with rifampicin, isoniazid, pyrazinamide and 
ethambutol regimen plus dexamethasone was started. 
Pulmonary evaluation showed negative Xpert MTB/
RIF®test of sputum and chest x-ray without significant 
changes. CT scan of the thoracic and lumbar spine showed 
osteolytic lesions in L3-L4, T8-T9 and T11-T12 suggestive 
of spinal tuberculosis. There was a significant improvement 
in symptoms, including the neurological deficit, and the 
patient became a febrile. He presented a 5-fold elevation 
of liver transaminases what obliged medical team to 
temporarily suspend the tuberculous meningoencephalitis 
regimen. He got discharged two months after admission.
Figure 1. Brain CT scan shows extensive basal meningeal 
enhancement
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MRI: magnetic resonance imaging, DWI: diffusion weighted imaging.
Figure 2. Brain MRI showedright internal capsule appearing hypointense on T1-weighted (2A) andhyperintense on T2-weighted (Fig 
2B) images. DWI shows (2C) restricted diffusion representing a parenchyma infarct area
DISCUSSION
Mycobacterium tuberculosis infection is acquired 
by inhalation of the bacilli through aerosols that reach 
and multiply in alveolar macrophages. The bacilli reach 
the CNS through the bloodstream after crossing the 
blood-brain barrier. Within CNS, the bacilli produce small 
granulomas in the meninges and cerebral parenchyma. 
These granulomas may remain inactive for several months 
or years. The decrease in host immunity may be a trigger 
for infection. After granuloma rupture in the cerebrospinal 
spaces, mycobacteria induce an intense immune response 
and, subsequently, the formation of exudate6.
Neurotuberculosis can be divided into subacute or 
chronic forms. The subacute form may have holocranial 
headache, irritability, behavioral changes, somnolence, 
anorexia, vomiting and abdominal pain, associated with 
fever, photophobia, vomiting and neck stiffness for 
more than two weeks. Eventually, it presents focal signs 
related to local ischemic syndromes or the involvement 
of cranial nerves (II, III, IV, VI and VII). There may 
be seen papilledema (intracranial hypertension). In 
chronic form, the patient may present headache and 
cranial nerve involvement for more than four weeks. 
Concomitant pulmonary disease occurs in up to 59% of 
cases. Another form of neurotuberculosis is the localized 
form (tuberculomas). In this presentation, slow growth 
of intracranial tuberculoma may occur, with signs and 
symptoms of intracranial hypertension. Fever may not be 
present5.
The delay in diagnosis and treatment usually leads 
to severe complications and even death7. Despite this, the 
clinical response to the treatment of neurotuberculosis is 
excellent when the diagnosis occurs before irreversible 
neurological damage. Early recognition is extremely 
important since clinical outcome largely depends on 
the stage at which therapy is initiated. Antituberculous 
empiric therapy should be initiated immediately in any 
patient with neurological abnormalities and cerebrospinal 
fluid (CSF) with low glucose concentration, high protein, 
lymphocytic pleocytosis and if TB is suspected. Adenosine 
deaminase (ADA) measurement in CSF may be a useful 
adjunct test for the diagnosis of tuberculous meningitis. 
However, high levels of CSF ADA can also be observed 
in bacterial infections, and there is no clear threshold for 
distinguishing neurotuberculosis from meningitis caused 
by other infectious agents4. The Xpert MTB/RIF®test 
has high sensitivity and specificity for diagnosis. It is 
based on nucleic acid amplification and also detects the 
resistance of mycobacteria to rifampicin (RIF) in less than 
2 hours. This test has improved the diagnosis and testing 
of drug susceptibility. It can be analyzed by sputum or 
CSF samples. However, its technical complexity and high 
cost still limits its adoption especially in low-resource 
institutions8.
CT or MRI of the skull may help in diagnosis. The 
three most common findings in tuberculous meningitis are 
hydrocephalus, basal meningeal thickening and cerebral 
parenchyma infarcts5. Thereported patient had all of these 
three findings: (1) leptomeningitis, the most common, 
represented by meningeal enhancement, (2) hydrocephalus 
due to the exudative pattern of CSF and (3) arteritis at 
skull base that compromises the quality of life due to 
neurological sequelae.
The treatment begins with an “intensive phase” 
consisting of a four-drug regimen that includes isoniazid, 
rifampicin, pyrazinamide, and ethambutol daily. This is 
followed by a “continuation phase” consisting of isoniazid 
and rifampin. Treatment usually consists of an initial period 
of 2 months of intensive therapy (with four drugs) followed 
by a prolonged continuation phase (with isoniazid and 
rifampicin) lasting 9 to 12 months depending on clinical 
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response and sensitivity to drugs of the isolate. The 
regimen for tuberculoma treatment is usually performed 
for 18 months. Standard treatment regimens are equally 
effective in HIV-negative and HIV-positive patients with 
neurotuberculosis9. Studies suggest that corticosteroids 
have reduced CSF inflammation and recovery time in 
patients with neurotuberculosis. Corticosteroids seem 
to reduce mortality, at least in the short term. However, 
dexamethasone probably does not prevent severe disability 
in survivors10.
CONCLUSION
The reported case assumes importance because it 
is a common disease in clinical practice but with a rare 
presentation. The CNV involvement if not diagnosed soon 
could lead the patient to a increased morbity and nearly 
to death.  The clinical and radiologic findings associated 
with the availability of Xpert MTB / RIF® test for rapid 
diagnosis was crucial for the institution of early treatment 
and the favorable clinical outcome.
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